ANTH — Anthera Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Anthera Pharma says J. Craig Thompson promoted to CEO and appointed to board
Brief: Anthera reports blisibimod BRIGHT-SC IgA nephropathy continues to demonstrate positive trends
Brief: Anthera says blisibimod CHABLIS-SC1 phase 3 study did not achieve primary endpoint in patients with active systemic lupus erythematosus
Brief: Anthera Pharmaceuticals reports third quarter loss per shr of $0.61
Brief: Anthera Pharmaceuticals agreed to sell preferred convertible stock to Biotechnology Value Fund
Brief: Anthera Pharmaceuticals names William Shanahan Jr. as chief medical officer
Brief: Anthera announces positive DSMB review in phase 3 solution study of Sollpura
Brief: Anthera Pharmaceuticals Q2 loss per share $0.35
Brief: Anthera provides clinical program updates for Blisibimod, Sollpura
Brief: Anthera Pharmaceuticals posts Q1 loss of $0.29/share
Brief: Anthera Pharma amends purchase agreement with Lincoln Park Capital
Brief: Anthera Pharmaceuticals appoints Brent Furse to board of directors
Brief: Anthera Pharmaceuticals Qtrly loss per share $0.18
Brief: Anthera Pharmaceuticals announces appointment of craig Thompson as president and chief operating officer
Brief: Anthera Pharmaceuticals Q3 loss per share $0.29
Brief: Anthera announces termination of blisibimod partnership in Japan by Zenyaku
Brief: Anthera Pharmaceuticals says offering of 3.3 mln shares priced at $7.50 per share
Brief: Anthera Pharmaceuticals says proposed public offering of common stock
Brief: Anthera Pharma says reached enrollment target in phase-3 trial with blisibimod